CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes Use of Intravascular Ultrasound Imaging in Percutaneous Coronary Intervention to Treat Left Main Coronary Artery Disease In acute HF and iron deficiency, IV ferric carboxymaltose reduced HF hospitalizations, but not CV death, at 1 y Poor R-wave progression as a predictor of sudden cardiac death in general population and subjects with coronary artery disease Clinical epidemiology of heart failure with preserved ejection fraction (HFpEF) in comparatively young hospitalized patients Intravascular ultrasound-guided implantation of drug-eluting stents to improve outcome: a meta-analysis Fractional flow reserve derived from CCTA may have a prognostic role in myocardial bridging Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study
|<<... 71 72 73 74 75 76 77 ...>>|

Original Research

JOURNAL：CBSMD Article Link

TAVR后的冠状动脉介入

CBSMD

Pre-reading


接受经导管主动脉瓣置换术(TAVR)治疗的患者的冠状动脉事件的累积风险较高，冠状动脉通路是否良好对于后续的冠脉介入是个挑战，最新一期的JACC Intervention为TAVR及后续的冠脉介入特刊

1. “Coronary Access After TAVR” 介绍了真实世界中通过CT明确的TAVR术后冠状动脉通路不良（unfavorable coronary access）患者的冠脉介入成功率数据后发现：

1）TAVR术后冠脉通路不良患者的冠脉介入成功率低于冠状动脉通路良好的患者。Evolut R/Evolut PRO 组(0.0% vs. 77.8%; p = 0.003)，SAPIEN 3 组(33.3% vs. 91.4%; p = 0.003) ；

2）提出了TAVR术中有助于保持良好冠状动脉通路的技术细节。


2. “Coronary Access After TAVR With a Self-Expanding Bioprosthesis: Insights From Computed Tomography”介绍了通过多层计算机断层CT观察到的经导管心脏瓣膜（THV）中位TAVR 30天后与左、右冠脉开口的相对解剖位置。



3. Low Risk TAVR试验 "Feasibility of Coronary Access and Aortic Valve Reintervention in Low-Risk TAVR Patients"指出TAVR治疗会对低风险患者的冠状通路造成影响, 或引发主动脉瓣再干预（TAVR-in-TAVR）时的冠脉阻塞。



4. “Coronary Protection to Prevent Coronary Obstruction During TAVR：A Multicenter International Registry”则比较了TAVR术后冠脉保护的两种方案，3年随访结果显示:

1) 通过支架保护冠脉开口后的心源性死亡率显著低于导丝保护后的心源性死亡率（7.8% vs. 15.8%, adjusted hazard ratio: 0.42; 95% confidence interval: 0.14 to 1.28; p = 0.13）;且通过置入支架保护的TAVR患者的明确的支架内血栓发生率不高（0.9%）；

2）通过导丝保护冠脉开口的患者需要预防延迟性的冠脉闭塞（delayed coronary occlusions），发生率为4.3%。



>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top